Vai al contenuto
Aperlena
Lingua:

Ireland - Laboratory reagents - Provision of Flow Cytometry Reagents, Antibodies, Platform-Specific Consumables and Single-Cell Genomics Reagents for Ongoing Research Activities

Aggiudicata Avviso di aggiudicazione Nessuna scadenza pubblicata
Segui questa gara

Le offerte sono chiuse. Un'aggiudicazione o una rettifica su questo avviso: un'email quando il registro lo vede. Accedi

  1. Aggiudicata
  2. Pubblicata

Descrizione

This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution. This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis, and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary, and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk, and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits, are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution.

Fonte ufficiale

Fonte: TED - Tenders Electronic Daily (Publications Office of the EU)

Verifica sempre i dettagli nell'avviso ufficiale.

Ultima verifica su TED - Tenders Electronic Daily (Publications Office of the EU) 1 mese fa

Vedi l'avviso ufficiale

Altro da questo committente

Profilo completo del committente

7 gare aperte in questo momento

Aggiudicazioni recenti

Cronologia delle modifiche

Ogni volta che una fonte ufficiale ha ripubblicato questo bando con contenuti diversi. Monitoriamo tutte le fonti che indicizziamo, comprese le copie regionali dello stesso bando.

  1. Leggi prima di partecipare
    • Data di aggiudicazione: Aggiudicato il 20 aprile 2026
    • Oggetto e criteri: La descrizione è stata ampliata. Rileggila prima di partecipare.

Segui questa gara e ti scriviamo appena cambia. Crea account

Gare simili

Contesto di mercato

Gara aperta media · Apparecchiature mediche e farmaceutici
10.142.739 €
9.882 aperte ora in Europa
Storico della stazione appaltante su Aperlena
119 avvisi tracciati · 84 aggiudicati
210.780.816 € in contratti aggiudicati

Non perderti nessuna gara come questa

2 nuovi avvisi per Apparecchiature mediche e farmaceutici in Irlanda negli ultimi 7 giorni. Ricevi un'email quando escono nuovi avvisi. Gratis.

Crea il mio avviso
Fonte

Scorciatoie da tastiera

Scorri un elenco senza toccare il mouse. Le scorciatoie restano inattive mentre scrivi in un campo.

j
Risultato successivo
k
Risultato precedente
Invio
Apri il risultato
n
Pagina successiva
p
Pagina precedente
c
Confronta questo risultato
s
Aggiungi questo risultato alla shortlist
/
Vai al campo di ricerca
?
Mostra queste scorciatoie
Esc
Chiudi